A new strategy was shown for the manipulation of autoantibody production in humans. Antiidiotypic antibody to human anti-DNA autoantibody was conjugated with neocarzinostatin (NCS), a cytotoxic agent, by using N-succimidyl 3-(2-pyridyldithio) propionate as a coupling agent. Human B cell clones, which produce anti-DNA autoantibodies, were killed by in vitro treatment with antiidiotype (Id)-NCS conjugates, while clones expressing an Id with irrelevant specificity were unaffected. These results indicate that treatment with anti-Id-NCS conjugates can act as a potent and specific means of generating immunosuppression of autoantibody production. This approach will have a significant advantage in aborting clones that are not effectively suppressed for the autoantibodies by anti-Id antibodies alone, and will result in a potential therapeutic treatment for systemic lupus erythematosus.
Introduction
There is a need for a new therapeutic approach for autoimmune diseases, since therapy is as yet unsatisfactory. Some autoantibodies have been believed to play a key role in the pathogenesis of immunological disorders (1, 2) . These observations have led to the realization that the specific manipulation ofthe production of autoantibodies, which contribute to the formation of lesions in systemic lupus erythematosus (SLE),' would be one recommended approach to therapy (3, 4) . In this respect, the use of antiidiotypic (Id) antibody might be an acceptable candidate for the in vivo regulation of autoimmune disorders (5-7). Anti-Id antibodies can not only induce the suppression of the in vitro production ofrheumatoid factors, but also improve the prognosis of NZB/W F1 mice (8, 9) . Anti-Id immunity, however, failed to suppress an already established spontaneous antibody production 1 . Abbreviations used in this paper: ds, double-stranded; DTT, dithiothreitol; EBV, Epstein-Barr virus; Id, idiotype; IF, immunofluorescent examination; NCS, neocarzinostatin; PDP, 3-(2-pyridyldithio)-propionylated; SLE, systemic lupus erythematosus; SPDP, N-succinidyl 3-(2-pyridyldithio) propionate; ss, single-stranded. (10) , and in another system the administration of anti-Id antibody elicited the production ofantibodies to thyroglobulin (1 1) . This variety in the results may be due to the complexity in antiId immunity, which includes a direct action to B cells and an activation of T cell circuits (12, 13) . It would therefore be desirable to develop a strategy in which the clones producing autoantibodies were specifically and strongly eliminated.
We established human B cell clones producing monoclonal anti-DNA autoantibodies ( 14) , which serve as useful models for anti-DNA antibody-producing cells in human SLE. Since antiId antibody to human anti-DNA antibody can specifically bind these clones (15) , anti-Id antibody in combination with a cytotoxic agent might be expected to selectively kill the Id-positive cells. Therefore we have developed a new procedure for the specific manipulation of autoantibody production, using anti-Id antibody coupled to neocarzinostatin (NCS).
Methods
Antibodies. Human monoclonal anti-double-stranded (ds) DNA or antisingle-stranded (ss) DNA antibodies were obtained from NE-I or 0-81 clones, which are B cell clones transformed by Epstein-Barr virus (EBV) infection (16 demonstrates that only 1F5-NCS inhibited the production of anti-DNA antibodies.
The above results suggest a selective killing of autoantibodyproducing clones by anti-Id antibody-conjugated NCS. To confirm this, DIE2-NCS was incubated with 0-81, NE-1, NE-13, NE-28, NE-29, or SA-1 (EBV-transformed B cell clones not producing anti-DNA antibody) for 6 h at 370C. After removing DIE2-NCS by washing three times with medium, each cell suspension was again incubated and tested for cell proliferation. Only 0-81 clones failed to grow and to produce anti-DNA antibodies (data not shown). Similar results were obtained in a mixed culture consisting of 0-81 and NE-I clones with IF5-NCS or DI E2-NCS. Fig. 3 shows the flow cytometry pattern for the idiotype expression in the latter, where the specific elimination of the clones by the relevant anti-Id-NCS was clearly demonstrated.
Discussion
This paper presents a new way for the specific elimination of autoantibody-producing clones. Would anti-Id antibodies be useful in the treatment of autoimmune states? Autoantibodies are a heterogenous population and bind to a large variety of antigens (17) (18) (19) (20) , suggesting a large number ofdifferent autoimmune clones. Ifthis is true, eliminating a single Id may not affect the majority of pathogenetic autoantibodies, which bear Id that do not crossreact (9, 10) . It has been demonstrated, however, that a limited number of anti-DNA antibodies, such as those with complement-fixing ability, cause the lesions seen in SLE (20, 21) . It would, therefore, be necessary to only control a subpopulation of antibodies to DNA to protect against damage. In addition, studies have shown that the Id repertoire of anti-DNA autoantibodies might be rather restricted in autoimmune mice (22, 23) . A high degree ofId crossreactivity was also found among human monoclonal anti-DNA antibodies (24) and the majority of sera in SLE (25 There is no opening of covalent bonds to release cytostatic activity at the target; and (e) It is easily crosslinked with monoclonal antibody because of its solubility in water. We wanted to produce anti-Id conjugates while minimally denaturing the antibodies.
We did this by using SPDP as a coupling agent, and it resulted in no decrease in either anti-Id binding or pharmacological activity of the bound NCS. The anti-Id-NCS conjugate was able to selectively eliminate the subpopulation of B cell clones bearing
Id on their surface. In this study, EBV-immortalized cells were used as targets for anti-Id-NCS. These clones produce monoclonal anti-DNA autoantibody and represent a low to intermediate percentage of the population of activated B cells when fractionated on a discontinuous Percoll gradient. The cells also express Ia and B4, and weakly express B1 and B2 antigents on their surface. In addition, their Ig receptors share an Id with antigen receptors. These findings are identical with activated B cells, especially those found in fractions containing anti-DNA antibody-producing cells in peripheral blood lymphocytes of SLE (Takai, unpublished data). Therefore, these clones appear to serve as excellent models for anti-DNA autoantibody-producing cells in humans and for therapy with anti-DNA antibody production. We are currently asking if this method is valuable for altering anti-DNA production by human lymphocytes. This approach will also help to clarify the importance of specific clones in immune network regulation and may provide important clues about the pathogenesis of SLE.
